These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38771544)

  • 1. Diagnostic accuracy of Afirma gene expression classifier, Afirma gene sequencing classifier, ThyroSeq v2 and ThyroSeq v3 for indeterminate (Bethesda III and IV) thyroid nodules: a meta-analysis.
    Vardarli I; Tan S; Görges R; Krämer BK; Herrmann K; Brochhausen C
    Endocr Connect; 2024 Jul; 13(7):. PubMed ID: 38771544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thyroseq v3, Afirma GSC, and microRNA Panels Versus Previous Molecular Tests in the Preoperative Diagnosis of Indeterminate Thyroid Nodules: A Systematic Review and Meta-Analysis.
    Silaghi CA; Lozovanu V; Georgescu CE; Georgescu RD; Susman S; Năsui BA; Dobrean A; Silaghi H
    Front Endocrinol (Lausanne); 2021; 12():649522. PubMed ID: 34054725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single Institution Experience with Afirma and Thyroseq Testing in Indeterminate Thyroid Nodules.
    Gortakowski M; Feghali K; Osakwe I
    Thyroid; 2021 Sep; 31(9):1376-1382. PubMed ID: 33764195
    [No Abstract]   [Full Text] [Related]  

  • 4. The Effect Modification of Ultrasound Risk Classification on Molecular Testing in Predicting the Risk of Malignancy in Cytologically Indeterminate Thyroid Nodules.
    Hu TX; Nguyen DT; Patel M; Beckett K; Douek M; Masamed R; Rhyu J; Kim J; Tseng CH; Yeh MW; Livhits MJ
    Thyroid; 2022 Aug; 32(8):905-916. PubMed ID: 35611970
    [No Abstract]   [Full Text] [Related]  

  • 5. Independent Comparison of the Afirma Genomic Sequencing Classifier and Gene Expression Classifier for Cytologically Indeterminate Thyroid Nodules.
    Angell TE; Heller HT; Cibas ES; Barletta JA; Kim MI; Krane JF; Marqusee E
    Thyroid; 2019 May; 29(5):650-656. PubMed ID: 30803388
    [No Abstract]   [Full Text] [Related]  

  • 6. Afirma Gene Sequencing Classifier Compared with Gene Expression Classifier in Indeterminate Thyroid Nodules.
    Endo M; Nabhan F; Porter K; Roll K; Shirley LA; Azaryan I; Tonkovich D; Perlick J; Ryan LE; Khawaja R; Meng S; Phay JE; Ringel MD; Sipos JA
    Thyroid; 2019 Aug; 29(8):1115-1124. PubMed ID: 31154940
    [No Abstract]   [Full Text] [Related]  

  • 7. Performance of Afirma Gene Sequencing Classifier versus Gene Expression Classifier in thyroid nodules with indeterminate cytology.
    Yang Z; Zhang T; Layfield L; Esebua M
    J Am Soc Cytopathol; 2022; 11(2):74-78. PubMed ID: 34366280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance of the Afirma genomic sequencing classifier versus gene expression classifier: An institutional experience.
    Wei S; Veloski C; Sharda P; Ehya H
    Cancer Cytopathol; 2019 Nov; 127(11):720-724. PubMed ID: 31536167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bethesda III and IV Thyroid Nodules Managed Nonoperatively After Molecular Testing With Afirma GSC or Thyroseq v3.
    Kim NE; Raghunathan RS; Hughes EG; Longstaff XR; Tseng CH; Li S; Cheung DS; Gofnung YA; Famini P; Wu JX; Yeh MW; Livhits MJ
    J Clin Endocrinol Metab; 2023 Aug; 108(9):e698-e703. PubMed ID: 36995878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of Afirma genomic sequencing classifier vs gene expression classifier in Bethesda category III thyroid nodules: An institutional experience.
    Zhang L; Smola B; Lew M; Pang J; Cantley R; Pantanowitz L; Heider A; Jing X
    Diagn Cytopathol; 2021 Aug; 49(8):921-927. PubMed ID: 34021740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of 167 Gene Expression Classifier (GEC) and ThyroSeq v2 Diagnostic Accuracy in the Preoperative Assessment of Indeterminate Thyroid Nodules: Bivariate/HROC Meta-analysis.
    Borowczyk M; Szczepanek-Parulska E; Olejarz M; Więckowska B; Verburg FA; Dębicki S; Budny B; Janicka-Jedyńska M; Ziemnicka K; Ruchała M
    Endocr Pathol; 2019 Mar; 30(1):8-15. PubMed ID: 30591992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene Expression Classifier vs Targeted Next-Generation Sequencing in the Management of Indeterminate Thyroid Nodules.
    Livhits MJ; Kuo EJ; Leung AM; Rao J; Levin M; Douek ML; Beckett KR; Zanocco KA; Cheung DS; Gofnung YA; Smooke-Praw S; Yeh MW
    J Clin Endocrinol Metab; 2018 Jun; 103(6):2261-2268. PubMed ID: 29590358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular testing for indeterminate thyroid nodules: Performance of the Afirma gene expression classifier and ThyroSeq panel.
    Jug RC; Datto MB; Jiang XS
    Cancer Cytopathol; 2018 Jul; 126(7):471-480. PubMed ID: 29637728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing Bias and Limitations of Clinical Validation Studies of Molecular Diagnostic Tests for Indeterminate Thyroid Nodules: Systematic Review and Meta-Analysis.
    DiGennaro C; Vahdatzad V; Jalali MS; Toumi A; Watson T; Gazelle GS; Mercaldo N; Lubitz CC
    Thyroid; 2022 Oct; 32(10):1144-1157. PubMed ID: 35999710
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of Afirma GEC and GSC to Nodules Without Molecular Testing in Cytologically Indeterminate Thyroid Nodules.
    Polavarapu P; Fingeret A; Yuil-Valdes A; Olson D; Patel A; Shivaswamy V; Matthias TD; Goldner W
    J Endocr Soc; 2021 Nov; 5(11):bvab148. PubMed ID: 34708178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Testing Versus Diagnostic Lobectomy in Bethesda III/IV Thyroid Nodules: A Cost-Effectiveness Analysis.
    Nicholson KJ; Roberts MS; McCoy KL; Carty SE; Yip L
    Thyroid; 2019 Sep; 29(9):1237-1243. PubMed ID: 31407625
    [No Abstract]   [Full Text] [Related]  

  • 17. Diagnostic performance of the second-generation molecular tests in the assessment of indeterminate thyroid nodules: A systematic review and meta-analysis.
    Lee E; Terhaar S; McDaniel L; Gorelik D; Gerhard E; Chen C; Ma Y; Joshi AS; Goodman JF; Thakkar PG
    Am J Otolaryngol; 2022; 43(3):103394. PubMed ID: 35241290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world Comparison of Afirma GEC and GSC for the Assessment of Cytologically Indeterminate Thyroid Nodules.
    San Martin VT; Lawrence L; Bena J; Madhun NZ; Berber E; Elsheikh TM; Nasr CE
    J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31665322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic performances of the Afirma Gene Sequencing Classifier in comparison with the Gene Expression Classifier: A meta-analysis.
    Vuong HG; Nguyen TPX; Hassell LA; Jung CK
    Cancer Cytopathol; 2021 Mar; 129(3):182-189. PubMed ID: 32726885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Afirma Gene Expression Classifier with Gene Sequencing Classifier in indeterminate thyroid nodules: A single-institutional experience.
    Geng Y; Aguilar-Jakthong JS; Moatamed NA
    Cytopathology; 2021 Mar; 32(2):187-191. PubMed ID: 33010060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.